Sarkopenia — możliwości diagnostyki i leczenia w warunkach POZ
Streszczenie
Sarkopenia (niewydolność mięśni), definiowana jako niski poziom siły, ilości i/lub jakości mięśni oraz sprawności fizycznej, jest zjawiskiem powszechnym wśród osób w podeszłym wieku. Diagnostyka sarkopenii powinna być pr zeprowadzana w przypadkach podejrzanych klinicznie oraz wśród tych pacjentów , którzy uzyskali co najmniej 4 pkt w badaniu przesiewowym, jakim powinien stać się kwestionariusz SARC-F. Sarkopenię można uznać za prawdopodobną i rozpocząć leczenie, jeżeli wykazano niską siłę ścisku dłoni tj. poniżej 16 kg w przypadku kobiet i 27 kg w przypadku mężczyzn lub wtedy, gdy w teście 5-krotnego wstawania z krzesła chorzy uzyskali czas przekraczający 15 sekund. Aby potwierdzić sarkopenię, należy wykazać niską jakość lub ilo ść mięśni przy użyciu metod takich jak DXA (uznawanej za „złoty standard”), BIA , CT lub MRI. P onieważ nie są one dostępne w warunkach opieki podstawowej, można je zastąpić pomiarem obwodu łydki z wynikiem poniżej 31 cm. W ocenie sprawności fizycznej obok testu „wstań i idź”, SPBB oraz 400-metrowego testu marszu, najpr zydatniejszy okazuje się test prędkości chodu na dystansie 4 metrów z punktem odcięcia poniżej ≤ 0,8 m/s, któr y potwierdza ciężką postać sarkopenii. Leczenie chorych z sarkopenią polega przede wszystkim na stosowaniu ćwiczeń, szczególnie oporowych w połączeniu z podażą białka na poziomie minimum 1–1,5 g/kg masy ciała/dobę.
Słowa kluczowe: sarkopeniaosoby starszeopieka podstawowa
Referencje
- Wilson D, Jackson T, Sapey E, et al. Frailty and sarcopenia: The potential role of an aged immune system. Ageing Res Rev. 2017; 36: 1–10.
- Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(1): 16–31.
- Janssen I. Evolution of sarcopenia research. Appl Physiol Nutr Metab. 2010; 35(5): 707–712.
- von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1(2): 129–133.
- Keller K, Engelhardt M. Strength and muscle mass loss with aging process. Age and strength loss. Muscles Ligaments Tendons J. 2013; 3(4): 346–350.
- Bauer J, Morley JE, Schols AM, et al. Sarcopenia: A Time for Action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019; 10(5): 956–961.
- An KOk, Kim J. Association of Sarcopenia and Obesity With Multimorbidity in Korean Adults: A Nationwide Cross-Sectional Study. J Am Med Dir Assoc. 2016; 17(10): 960.e1–960.e7.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–423.
- Papadopoulou SK. Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients. 2020; 12(5).
- Shafiee G, Keshtkar A, Soltani A, et al. Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. J Diabetes Metab Disord. 2017; 16: 21.
- Papadopoulou SK, Tsintavis P, Potsaki P, et al. Differences in the Prevalence of Sarcopenia in Community-Dwelling, Nursing Home and Hospitalized Individuals. A Systematic Review and Meta-Analysis. J Nutr Health Aging. 2020; 24(1): 83–90.
- Han A, Bokshan SL, Marcaccio SE, et al. Diagnostic Criteria and Clinical Outcomes in Sarcopenia Research: A Literature Review. J Clin Med. 2018; 7(4).
- Bahat G, Yilmaz O, Kılıç C, et al. Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures. J Nutr Health Aging. 2018; 22(8): 898–903.
- Krzymińska-Siemaszko R, Deskur-Śmielecka E, Kaluźniak-Szymanowska A, et al. Polish version of SARC-F to assess sarcopenia in older adults: An examination of reliability and validity. PLoS One. 2020; 15(12): e0244001.
- Beaudart C, McCloskey E, Bruyère O, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016; 16(1): 170.
- Cesari M, Kritchevsky SB, Newman AB, et al. Health, Aging and Body Composition Study. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009; 57(2): 251–259.
- Landi F, Onder G, Russo A, et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr. 2014; 33(3): 539–544.
- Kuys SS, Peel NM, Klein K, et al. Gait speed as a measure in geriatric assessment in clinical settings: a systematic review. J Gerontol A Biol Sci Med Sci. 2013; 68(1): 39–46.
- Abellan van Kan G, Rolland Y, Andrieu S, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009; 13(10): 881–889.
- Bischoff HA, Stähelin HB, Monsch AU, et al. Identifying a cut-off point for normal mobility: a comparison of the timed 'up and go' test in community-dwelling and institutionalised elderly women. Age Ageing. 2003; 32(3): 315–320.
- Dodds R, Denison HJ, Ntani G, et al. Birth weight and muscle strength: a systematic review and meta-analysis. J Nutr Health Aging. 2012; 16(7): 609–615.
- Bloom I, Shand C, Cooper C, et al. Diet Quality and Sarcopenia in Older Adults: A Systematic Review. Nutrients. 2018; 10(3).
- Sayer AA, Syddall H, Martin H, et al. The developmental origins of sarcopenia. J Nutr Health Aging. 2008; 12(7): 427–432.
- Kalinkovich A, Becker M, Livshits G, et al. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017; 35(9): 200–221.
- Tian S, Xu Y. Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2016; 16(2): 155–166.
- Beckwée D, Delaere A, Aelbrecht S, et al. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. J Nutr Health Aging. 2019; 23(6): 494–502.
- Harber MP, Konopka AR, Undem MK, et al. Aerobic exercise training induces skeletal muscle hypertrophy and age-dependent adaptations in myofiber function in young and older men. J Appl Physiol (1985). 2012; 113(9): 1495–1504.
- Panayiotou G, Paschalis V, Nikolaidis MG, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports. 2013; 23(5): 556–567.
- Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013; 14(8): 542–559.
- Bauer J, Biolo G, Cederholm T, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013; 14(8): 542–559.
- Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009; 12(1): 86–90.
- Remelli F, Vitali A, Zurlo A, et al. Vitamin D Deficiency and Sarcopenia in Older Persons. Nutrients. 2019; 11(12).
- Annweiler C, Schott AM, Berrut G, et al. Vitamin D-related changes in physical performance: a systematic review. J Nutr Health Aging. 2009; 13(10): 893–898.
- Lauretani F, Semba RD, Bandinelli S, et al. Carotenoids as protection against disability in older persons. Rejuvenation Res. 2008; 11(3): 557–563.
- Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011; 93(2): 402–412.
- Morley JE, Morley JE. Frailty and Sarcopenia: The New Geriatric Giants. Rev Invest Clin. 2016; 68(2): 59–67.
- Malmstrom TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1): 28–36.
- Piotrowicz K, Głuszewska A, Czesak J, et al. SARC-F as a case-finding tool for sarcopenia according to the EWGSOP2. National validation and comparison with other diagnostic standards. Aging Clin Exp Res. 2021; 33(7): 1821–1829.